Ipo Price Of Biocon

Ipo price of biocon

Ipo price of biocon

Biocon Files Draft Red Herring Prospectus with SEBI for IPO

Bangalore, January 28, 2004

HIGHLIGHTS

- IPO to comprise fresh issue of an aggregate of 10 million equity shares; Price Discovery through the book building process.



- Proceeds from IPO to be used for setting up new facilities to augment Fermentation capacity.

- Listing on The Stock Exchange, Mumbai and National Stock Exchange of India Limited.

Ipo price of biocon

10% of enhanced equity to be offered in the IPO

- DSP Merrill Lynch Limited and Kotak Mahindra Capital Company Limited are the Book Running Lead Managers while HSBC Securities & Capital Markets (India) Pvt.

Limited is the Co-Book Running Lead Manager.

Efficiency

Karvy Consultants Limited is the registrar to the issue.

Biocon Limited, India's pioneering biotechnology company, has filed its Draft Red Herring Prospectus for its forthcoming public issue with SEBI.

Ipo price of biocon

This was done on Friday, January 23 2004. The Offer is for a fresh issue of 10 million equity shares of Rs.

Options trading strategies pdf download

5 each.

The issue is proposed through a 100% book-building scheme. The Offer would constitute 10% of the fully diluted post issue paid up capital of the Company. Biocon will list the equity shares on the Stock Exchange, Mumbai and National Stock Exchange of India Limited.

Ipo international student insurance

Biocon's consolidated revenues of Rs. 399 crores and net profits of Rs. 95 crores for the 9-month period ended December 31 2003, reflected a 41% and 119% increase respectively, over full year results for fiscal 2003.

Price Chart

Upto 2002-03, Biocon's net profits, including that of its subsidiaries Syngene and Clinigene, has grown at a 3-year CAGR of 85%.

Consolidated Net Worth as at 31 December 2003 was Rs. 230 Crores

Commenting on the IPO, Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, "We intend to utilize the proceeds of the public offering for Biocon's expansion program, which encompasses a large-scale statins facility and a state-of-the-art R&D laboratory."

DSP Merrill Lynch Limited and Kotak Mahindra Capital Company Limited are the Book Running Lead Managers while HSBC Securities & Capital Markets (India) Pvt Limited is the Co-Book Running Lead Manager.

Karvy Consultants Limited is the registrar to the issue.

ABOUT BIOCON

Established in 1978, Biocon Limited is one of India's premier biotechnology companies.

Ipo price of biocon

Biocon and its two subsidiary companies, Syngene International Pvt Ltd and Clinigene International Pvt Ltd form a fully integrated biotechnology enterprise, specialising in biopharmaceuticals, custom research, clinical research and enzymes. With successful initiatives in clinical development, bioprocessing and global marketing, Biocon delivers products and solutions to partners and customers across 50 countries. Visit us at www.biocon.com

This is not an offer of securities for sale in the United States.

Quick Links

Securities of Biocon Limited may not be offered or sold in the United States absent registration or an exemption from registration. Any securities to be offered in Biocon's IPO have not been and will not be registered under the U.S.

BIOCON (TREND REVERSAL ) #Biocon #stocks #TechnicalAnalysis #Trading

Securities Act of 1933.